K-Ras, PTEN, c-Met, and mutations in the EGFR tyrosine kinase domain, but not overall EGFR expression, are associated with resistance to EGFR tyrosine kinase inhibitors erlotinib and gefitinib in lung cancer, as reviewed in [30,31]. Here, EGFR is linked to lung carcinoma.